#1 Clinical Trials Search in Europe

2′-O-(2-Methoxyethyl) Modified Antisense Oligonucleotide Targeting Ube3A Antisense Transcript Rna

This article discusses a clinical trial investigating the use of ION582, a new drug designed to treat Angelman syndrome. ION582 is a specially modified antisense oligonucleotide that targets the UBE3A antisense transcript RNA. The study aims to assess the safety, tolerability, and effectiveness of this innovative treatment approach for patients with Angelman syndrome, a rare genetic disorder affecting the nervous system.

Table of Contents

What is ION582?

ION582 is a new medication being developed to treat Angelman syndrome. It’s classified as an antisense oligonucleotide (ASO), which is a type of drug that can influence how genes work in our bodies[1]. The full name of the active substance in ION582 is “2′-O-(2-methoxyethyl) modified antisense oligonucleotide targeting UBE3A antisense transcript RNA”. This long name describes how the drug is designed to work specifically for Angelman syndrome.

Understanding Angelman Syndrome

Angelman syndrome is a rare genetic condition that affects the nervous system. It causes developmental delays, problems with speech and balance, intellectual disability, and sometimes seizures. This condition is caused by problems with a gene called UBE3A[1].

How ION582 Works

ION582 is designed to target a specific part of the genetic material in cells related to Angelman syndrome. It aims to influence how the UBE3A gene works. By doing this, researchers hope that ION582 might help improve some of the symptoms of Angelman syndrome[1].

Current Clinical Trial

ION582 is currently being studied in a clinical trial. This trial is called a Phase 1-2a study, which means it’s one of the early stages of testing a new drug. The main goals of this study are to check if ION582 is safe to use and to understand how it works in the body[1].

Who Can Participate in the Trial?

The study is looking for people with specific characteristics. Here are some of the main requirements:

  • Participants must have a confirmed diagnosis of Angelman syndrome caused by a specific type of genetic change[1].
  • They should be between 2 and 50 years old[1].
  • They should be on stable treatments for at least 3 months before starting the study. This includes medications for epilepsy, behavior management, or sleep issues[1].

There are also some reasons why a person might not be able to participate in the study. For example:

  • Having certain types of Angelman syndrome caused by different genetic changes[1].
  • Having other significant health conditions that might make the study unsafe for the participant[1].
  • Having had certain other treatments in the past, like gene therapy[1].

Safety and Effects Being Studied

The main focus of this study is to check how safe ION582 is and how well people tolerate it. Researchers will be looking at:

  • Any side effects that occur and how severe they are[1].
  • Changes in vital signs (like heart rate and blood pressure)[1].
  • Changes in laboratory test results[1].

They will also study how ION582 moves through the body, including:

  • How much of the drug appears in the blood, spinal fluid, and urine[1].
  • How long it takes for the drug to reach its highest level in the body[1].
  • How long it takes for the body to remove the drug[1].

How ION582 is Administered

ION582 is given through a procedure called intrathecal injection. This means the medication is injected directly into the fluid surrounding the brain and spinal cord. This method is chosen to help the drug reach the nervous system more effectively[1].

Aspect Details
Drug Name ION582
Drug Type 2′-O-(2-Methoxyethyl) Modified Antisense Oligonucleotide
Target Condition Angelman syndrome
Administration Method Intrathecal injection
Study Phase Phase 1-2a
Primary Objective Evaluate safety and tolerability
Secondary Objectives Characterize pharmacokinetics in cerebrospinal fluid, plasma, and urine
Age Range of Participants 2-50 years
Key Inclusion Criteria Documented Angelman syndrome diagnosis, stable standard care treatments
Key Exclusion Criteria Paternal uniparental disomy, imprinting defect, poorly controlled seizures, prior oligonucleotide or gene therapy treatment

FAQ

  • What is ION582 and how does it work? ION582 is a 2'-O-(2-Methoxyethyl) modified antisense oligonucleotide that targets the UBE3A antisense transcript RNA. It's designed to potentially treat Angelman syndrome by modifying the expression of specific genes related to the condition.
  • Who can participate in this clinical trial? The trial is open to male and female patients aged 2-50 years with a documented diagnosis of Angelman syndrome caused by ubiquitin-protein ligase E3A deletion or UBE3A mutation. Participants must be on stable standard care treatments for at least 3 months before the first dose.
  • How is ION582 administered in the trial? ION582 is administered intrathecally, which means it's injected directly into the fluid surrounding the brain and spinal cord. The study will evaluate multiple intrathecal bolus administrations at ascending dose levels.
  • What are the main objectives of this clinical trial? The primary objective is to evaluate the safety and tolerability of ION582 in patients with Angelman syndrome. Secondary objectives include characterizing the drug's pharmacokinetics in cerebrospinal fluid, plasma, and urine.
  • Are there any specific exclusion criteria for the trial? Yes, some key exclusion criteria include having Angelman syndrome caused by paternal uniparental disomy or imprinting defect, poorly controlled seizures, previous treatment with oligonucleotides, and any prior use of gene therapy. Other medical conditions that might pose a safety risk or interfere with the study procedures may also exclude participation.

Ongoing Clinical Trials on 2′-O-(2-Methoxyethyl) Modified Antisense Oligonucleotide Targeting Ube3A Antisense Transcript Rna

  • A Phase 3 study to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome

    Recruiting

    3 1 1
    Investigated drugs:
    Germany Italy Poland Spain

  • Study on the Safety and Effects of ION582 for Patients with Angelman Syndrome

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy

Glossary

  • Angelman syndrome: A rare genetic disorder that affects the nervous system, causing developmental delays, intellectual disability, speech problems, and movement issues.
  • Antisense oligonucleotide (ASO): A short piece of synthetic DNA or RNA that can bind to specific RNA molecules, potentially altering gene expression or protein production.
  • Intrathecal administration: A method of delivering medication directly into the fluid surrounding the brain and spinal cord.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • UBE3A: A gene that, when mutated or deleted, is responsible for causing Angelman syndrome.
  • Cerebrospinal fluid: The clear, colorless fluid that surrounds the brain and spinal cord, protecting and nourishing these organs.
  • Bolus administration: A method of giving a medication where a drug is injected all at once, rather than slowly over time.
  • Status Epilepticus: A serious condition where a seizure lasts longer than 5 minutes or when seizures occur close together without recovery between them.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-ion582-for-patients-with-angelman-syndrome/